Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Deferred Taxes: 2009-2024

Historic Deferred Taxes for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $260,000.

  • Anika Therapeutics' Deferred Taxes rose 101.63% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $252,000, marking a year-over-year increase of 113.87%. This contributed to the annual value of $260,000 for FY2024, which is 104.11% up from last year.
  • Latest data reveals that Anika Therapeutics reported Deferred Taxes of $260,000 as of FY2024, which was up 104.11% from -$6.3 million recorded in FY2023.
  • Anika Therapeutics' 5-year Deferred Taxes high stood at $260,000 for FY2024, and its period low was -$6.3 million during FY2023.
  • Moreover, its 3-year median value for Deferred Taxes was -$5.3 million (2022), whereas its average is -$3.8 million.
  • In the last 5 years, Anika Therapeutics' Deferred Taxes tumbled by 546.22% in 2020 and then soared by 104.11% in 2024.
  • Over the past 5 years, Anika Therapeutics' Deferred Taxes (MRY) stood at -$3.5 million in 2020, then soared by 50.16% to -$1.8 million in 2021, then crashed by 198.41% to -$5.3 million in 2022, then fell by 20.06% to -$6.3 million in 2023, then soared by 104.11% to $260,000 in 2024.
  • Its last three reported values are $260,000 in FY2024, -$6.3 million for FY2023, and -$5.3 million during FY2022.